close and back to page

Novartis: From Patient to Patient Advocate: How a Cancer Diagnosis Fueled a New Career Path

Elyse Spatz Caplan's cancer diagnosis impacted her life in more ways than 1.

Spatz Caplin, far right, with her family

Originally Published by Novartis.

Almost 30 years ago, Elyse Spatz Caplan's oldest son hopped on a bus to go to summer camp while she drove to the hospital for surgery. A young mom of 3 boys under the age of 8, she had recently been diagnosed with breast cancer and was dealing with feelings of unease and uncertainty about the future.

Read More Show Less

Novartis: Breaking Through Barriers

Finding a virus that crosses the blood-brain barrier could change how some neurological diseases are treated.

Originally Published by Novartis.

By Goran Mijuk

Brian Kaspar speaks with a soft but determined voice, choosing every word carefully.

The 45-year-old researcher, who serves as chief scientific officer of US-based gene therapy company AveXis, is extremely focused. This has helped him in his pursuit to develop gene therapy for patients suffering from deadly motor neuron diseases.

Read More Show Less

Novartis: Artificial Intelligence Decodes Cancer Pathology Images

Novartis researchers are collaborating with tech startup PathAI to search for hidden information in pathology slides.

Originally Published by Novartis.

For 150 years, pathologists have been looking through microscopes at tissue samples mounted on slides to diagnose cancer. Each assessment is weighty: Does this patient have cancer or not?

Read More Show Less

Novartis: The Importance of Caregivers

Melanoma survivor T.J. Sharpe discusses his personal experience with cancer and the important role caregivers play in a patient's road to recovery.

Originally Published by Novartis.

By T.J. Sharpe

Behind every cancer patient, there is likely a caregiver whose critical role is often overlooked. By helping patients understand and process their disease, caregivers can positively impact patients' treatment decisions as well as their ability to adjust to the new reality of being under an oncologist's care.

Read More Show Less

Novartis Announces Clinical Collaboration with Pfizer to Advance the Treatment of NASH

There are currently no approved treatments for NASH, a progressive form of non-alcoholic fatty liver disease, which affects up to 6.5% of the population worldwide.

Originally Published by Novartis.

Novartis announced that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919). The financial details of this transaction are not disclosed.

Read More Show Less

Novartis: Alcon to Develop SMART Suite Digital Health Platform for Cataract Surgery

As an open, secure cloud-enabled ecosystem, SMART Suite by Alcon will bring greater efficiency to the cataract surgical process and help optimize outcomes for patients.

Originally Published by Novartis.

Alcon, the global leader in eye care and a division of Novartis, announced plans to develop the SMART Suite by Alcon, an innovative, digital platform that is designed to streamline, simplify and improve cataract surgery for surgeons and patients.

Read More Show Less

Novartis: Women in Science: Marjorie Eiref

Marjorie Eiref, Head of Operations for Neuroscience Research at Novartis, describes how her family medical history has impacted her career.

Originally Published by Novartis.

By Susan C. DiClemente

Many people who work in the healthcare industry do so because they want to help people. For Marjorie Eiref, family also plays a key role. Eiref, who serves as Head of Operations for Neuroscience Research at Novartis, explains how her family medical history has helped shape her 25-year career in pharmaceutical research operations.

What motivates you to work in the healthcare industry?

I have worked in pharmaceutical research operations for 25 years. The reason that I love my work and why I wake up every morning excited about coming to Novartis is because I'm very passionate about drug discovery, specifically in the neuroscience field. One in three Americans is affected by a psychiatric or neurodegenerative disease. I have a brother who is autistic. He is 47 years old and lives in a group home. I am his legal guardian. My uncle was a Vietnam veteran with classic schizophrenia. My grandmother had Alzheimer's, and I watched her slow debilitation. When I sit in lab meetings or in leadership team meetings, I am always thinking about my family and how our research and decisions relate back to all affected patients and their families and caregivers. Every decision we make in early research has an impact eventually on these people and their comfort, happiness and livelihood.

What personal qualities or experiences have you leveraged to achieve your goals?

My three greatest personal strengths are compassion, loyalty and courage. But I think my vulnerabilities and weaknesses are the things that have made me stronger in my life. I have been a single mom for over 12 years. Both of my children are happy and doing well in their university studies. But the early years, when they were younger and I was working full-time, were very challenging. One of the ways that I survived was to be actively involved, to always volunteer whenever I could help out with watching other people's children [and] helping at soccer games or school events. I never knew when I might need to call in a favor from someone else. This applies to our careers; if you do things to help your community – truly support other people – it always comes back to help you. Karma exists. It is important to be generous and supportive of others. It takes a village to accomplish many things, and we have an amazing community at Novartis.

What opportunities have helped you advance in your career, and how will you pay it forward?

I have been very fortunate. The first woman who I worked for was not just a manager but a mentor. Since then, it has always been very important for me to mentor other people, especially women. When people reach out for advice about career development, professional job skills, recruitment opportunities, I am always eager to help or share my perspective. It is important to network and bridge our knowledge and skills with others.

Novartis: Sandoz Healthcare Access Challenge Returns, Seeking Digital Solutions to Local Healthcare Access Challenges

Despite major advances in modern medicine, universal access to healthcare remains the largest unmet medical need.

Originally Published by Novartis.

Sandoz, the Novartis generics and biosimilars division, announces the launch of the second Sandoz Healthcare Access Challenge (HACk).

The Sandoz HACk is a global competition that invites entrepreneurs and innovators in the field of digital technology to submit inspirational ideas with the potential to complement - or even positively disrupt - established approaches to driving access to healthcare. Sandoz HACk opens for entries October 4, closing on November 30, 2018.

Read More Show Less

Novartis: Alcon Announces Voluntary Global Market Withdrawal of CyPass Micro-Stent for Surgical Glaucoma

Decision based on five-year data from COMPASS-XT long-term safety study; Alcon advises ophthalmic surgeons to cease further implantation.

Originally Published by Novartis.

Reflecting its uncompromising commitment to patient safety, Alcon announced an immediate, voluntary market withdrawal of the CyPass Micro-Stent from the global market. In addition, Alcon advises surgeons to immediately cease further implantation with the CyPass Micro-Stent and to return any unused devices to Alcon. This decision and corresponding recommendation is based on an analysis of five-year post-surgery data from the COMPASS-XT long-term safety study.

Read More Show Less

Novartis Reports Favorable Results for Alpha Specific PI3K Inhibitor BYL719

Full results will be submitted to an upcoming medical congress and Novartis will initiate discussions with regulatory authorities worldwide.

Originally Published by Novartis.

Novartis announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint showing an improvement in progression-free survival (PFS). SOLAR-1 is evaluating BYL719 in combination with fulvestrant compared to fulvestrant alone in postmenopausal women and men with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) PIK3CA-mutant advanced or metastatic breast cancer that progressed on or following aromatase inhibitor treatment with or without a CDK4/6 inhibitor[1].

Read More Show Less

Novartis appoints Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer

Dr. Moosmayer is a recognized global leader in Ethics and Compliance. Since 2013, he has been Chair of the Anti-Corruption Taskforce of the Business and Industry Advisory Committee at the Organization for Economic Co-operation and Development (OECD).

Originally Published by Novartis.

Novartis announced the appointment of Dr Klaus Moosmayer as Chief Ethics, Risk and Compliance Officer. He will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive Committee of Novartis (ECN). Dr. Moosmayer will join Novartis on December 1, 2018 and will be based in Basel, Switzerland. He succeeds Shannon Thyme Klinger who was recently appointed Group General Counsel.

Read More Show Less

Novartis Marks a New Era for Migraine Patients with the EU Approval of Aimovig, a First-of-its-Kind Treatment Specifically Designed for Migraine Prevention

Migraine is the third leading cause of disability in people under 50, leading to severe disruption to the personal and professional lives of millions of sufferers.

Originally Published by Novartis.

Novartis announced that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days per month. Aimovig is the first and only treatment specifically designed for migraine prevention to be approved in the European Union, Switzerland, the US and Australia. It works by blocking a receptor called the calcitonin gene-related peptide receptor (CGRP-R) which plays a critical role in mediating the incapacitating pain of migraine. In the extensive clinical program of 2,600 patients, those on Aimovig experienced significant reductions in their number of migraine days per month, with a safety and tolerability profile similar to placebo[1]-[3]. Aimovig can be self-administered or administered by another trained person every four weeks with the SureClick® autoinjector pen, an established device commonly used for a range of different conditions.

Read More Show Less
© Copyright 2018 — DiversityInc All Rights Reserved.